Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listFulvestrant

Fulvestrant

Synonym(s):(7α,17β)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol;Faslodex;Fulvestrant;

  • CAS NO.:129453-61-8
  • Empirical Formula: C32H47F5O3S
  • Molecular Weight: 606.77
  • MDL number: MFCD00903953
  • EINECS: 642-998-6
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 23:02:33
Fulvestrant Structural

What is Fulvestrant?

Toxicity

There is no clinical experience with overdosage in humans.

Description

Fulvestrant was launched in the US as a novel once monthly injectable steroidal estrogen antagonist for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following estrogen therapy. This 7a-alkylsulphinyl derivative of estradiol can be prepared in 10 steps from 6,7- didehydro-19-nor-testosterone by successive conjugate addition of the organocuprate derived from O-protected 9-bromononan-l-o1 followed by aromatization of the resulting enone, then activation of the protected primary alcohol, substitution with 4,4,5,5,5- pentafluoropentanthiol and oxidation to the sulfoxide. Fulvestrant is the first “pure” estrogen antagonist from a novel class known as selective estrogen receptor down regulators (SERDs). It binds to the estrogen receptor (ER), with affinity close to that of estradiol and 100 fold greater than that of tamoxifen (a partial estrogen antagonist), preventing estrogen-stimulated gene activation, thereby interfering with the estrogenrelated processes essential for cell-cycle completion. Fulvestrant also appears to downregulate the ER by 80-90% often to non detectable level both in vitro and in vivo. In comparison to tamoxifen, fulvestrant is devoid of systemic estrogenic activity, it displays no uterotrophic activity and is able to block the uterine stimulation of estradiol or tamoxifen. Furthermore, fulvestrant completely blocks the cell growth in tamoxifen-resistant breast cancer cell-lines and prevents growth of tamoxifen resistant tumor in mice. In clinical trials, it was also shown that fulvestrant is comparable to anastrozole (a third generation aromatase inhibitor) both in efficacy and tolerability in postmenopausal women with tamoxifen-resistant advanced breast cancers.

Chemical properties

White or almost white powder.

Originator

Astra Zeneca (UK)

The Uses of Fulvestrant

A novel steroidal estrogen antagonist reported to lack any partial agonist activity. Antineoplastic (hormonal).

The Uses of Fulvestrant

antiestrogen

Definition

ChEBI: A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.

Indications

For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

What are the applications of Application

ICI 182,780 is an estrogen receptor inhibitor and GPR30 activator

Background

Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer

brand name

Faslodex (AstraZeneca).

General Description

Fulvestrant, 7α-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17β-diol (Faslodex), is an antagonist structurally based onthe estradiol structure, with a long, substituted alkyl chainattached at the 7α-position of the steroid skeleton. Whenbound to the ERs, this alkyl chain induces a conformationof the receptor distinctive from that formed upon estradiolor tamoxifen binding, preventing agonist action.Fulvestrant is a pure antagonist at both ERαand ERβandan ER downregulator (stimulates degradation of the ER),completely lacking the agonist activity that is seen with tamoxifenor raloxifene. The different pharmacological profileof fulvestrant allows the use of this agent in womenwho have had disease progression after prior antiestrogentherapy (typically tamoxifen), providing an alternative toaromatase inhibitors.

Biological Activity

A high affinity estrogen receptor antagonist (IC 50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo . Also high affinity agonist at the membrane estrogen receptor GPR30.

Biochem/physiol Actions

Fulvestrant (ICI 182,780) is a selective estrogen receptor down-regulator (SERD). Fulvestrant is a high affinity estrogen receptor antagonist. IC50 = 0.29 nM. Fulvestrant is the first "pure" antiestrogen with no agonistic activity both in vitro and in vivo.

Pharmacokinetics

Fulvestrant for intramuscular administration is an estrogen receptor antagonist without known agonist effects.

Clinical Use

Treatment of postmenopausal women with oestrogenreceptor- positive, locally advanced or metastatic breast cancer

Side Effects

Side effects appear to be minimal and include several GI symptoms , headache, and hot flashes . There is no clinical evidence of uterine stimulation or laboratory evidence of stimulation of endometrial carcinoma models. Fulvestrant should not be adm inistered to women who are pregnant, who are taking antic oagulants, or who have thrombocytopenia.

Synthesis

Fulvestrant is administered as a once a month i. m. injection. Several routes for the synthesis of fulvestrant (12) were published. One of the best routes is depicted in the scheme. The conjugate addition of Grignard reagent derived from bromide 130 with dienone 129 gave adduct 131 as a mixture of 7|á- and 7|?-isomers in a ratio of 2.5:1 in 90-95% yield. Aromatization of the A-ring with copper bromide/lithium bromide in acetic acid followed by hydrolysis of the ester group provided diol 132 in 80-85% yield. Oxidation of the side chain from sulfite to sulfone followed by crystallization provided fulvestrant (12) in 30% overall yield from dienone 129.

Synthesis_129453-61-8

Metabolism

The metabolism of fulvestrant has not been fully evaluated, but involves combinations of a number of possible biotransformation pathways analogous to those of endogenous steroids. Identified metabolites (includes 17-ketone, sulphone, 3-sulphate, 3- and 17-glucuronide metabolites) are either less active or exhibit similar activity to fulvestrant in anti-oestrogen models.
Fulvestrant is eliminated mainly in metabolised form. The major route of excretion is via the faeces.

Metabolism

Metabolism of fulvestrant appears to involve combinations of a number of possible biotransformation pathways analogous to those of endogenous steroids, including oxidation, aromatic hydroxylation, conjugation with glucuronic acid and/or sulphate at the 2, 3 and 17 positions of the steroid nucleus, and oxidation of the side chain sulphoxide. Identified metabolites are either less active or exhibit similar activity to fulvestrant in antiestrogen models. Studies using human liver preparations and recombinant human enzymes indicate that cytochrome P-450 3A4 (CYP 3A4) is the only P-450 isoenzyme involved in the oxidation of fulvestrant; however, the relative contribution of P-450 and non-P-450 routes in vivo is unknown.

storage

Room temperature

References

Osborne et al. (2004), Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action; Br. J. Cancer 90 (Suppl 1):S2 Thomas et al. (2005), Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells; Endocrinology 146 624 Wardley (2002), Fulvestrant: a review of its development, pre-clinical and clinical data; Int. J. Clin. Pract. ?56 305 Castro et al. (2012),?Coumestrol has neuroprotective effects before and after cerebral ischemia in female rats; Brain Res.?1474 82 Blackburn et al. (2018),?Fulvestrant for the treatment of advanced breast cancer; Expert Rev. Anticancer Ther. 18 619

Properties of Fulvestrant

Melting point: 104-106°C
Boiling point: 674.8±55.0 °C(Predicted)
Density  1.201±0.06 g/cm3(Predicted)
storage temp.  2-8°C
solubility  DMSO: >5mg/mL
form  powder
pka 10.27±0.70(Predicted)
color  White
Stability: Stable for 2 years as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
CAS DataBase Reference 129453-61-8(CAS DataBase Reference)

Safety information for Fulvestrant

GHS Hazard Statements H413:Hazardous to the aquatic environment, long-term hazard
Precautionary Statement Codes P273:Avoid release to the environment.
P501:Dispose of contents/container to..…

Computed Descriptors for Fulvestrant

InChIKey VWUXBMIQPBEWFH-WCCTWKNTSA-N
SMILES [C@@]12([H])[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC3C=C(O)C=CC=3[C@@]1([H])CC[C@]1(C)[C@H](CC[C@@]21[H])O |&1:0,2,32,36,38,41,r|

Fulvestrant manufacturer

Ralington Pharma

1Y
Phone:+91-9687771722
Whatsapp: +91- 9687771722
product: Fulvestrant 98%
Inquiry

Sakar Healthcare

1Y
Phone:+91-9967572302
Whatsapp: +91-9967572302
product: Fulvestrant 129453-61-8 98%
Inquiry

Sumar Biotech LLP

1Y
Phone:+91-9824575381
Whatsapp: +91-9824575381
product: 129453-61-8 Fulvestrant 98%
Inquiry

BDR Pharmaceuticals International Pvt Ltd

1Y
Phone:+917718884418
Whatsapp: +91-7718884418
product: 129453-61-8 98%
Inquiry

Beta Drugs

1Y
Phone:+917015991921
Whatsapp: +91-7015991921
product: Fulvestrant 98%
Inquiry

Shreyaa Medilife Private Limited

1Y
Phone:+919879513108
Whatsapp: +91-9879513108
product: Fulvestrant 129453-61-8 98%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.